Director John R. Stuelpnagel filed a Form 4 with the SEC on August 13, 2026, disclosing the sale of 20,000 shares of 10x Genomics, Inc. Class A Common Stock on August 11, 2026.

Key Highlights

  • Reporting person: John R. Stuelpnagel, Director of 10x Genomics, Inc. (NASDAQ:TXG)
  • First sale: 17,000 shares of Class A Common Stock sold at a weighted average price of $57.5812 per share on August 11, 2026
  • Second sale: 3,000 shares of Class A Common Stock sold at $58.725 per share on August 11, 2026
  • Remaining ownership: 348,436 shares of Class A Common Stock held directly following the transactions
  • Price range: The 17,000-share transaction was executed in multiple trades at prices ranging from $57.50 to $58.1525, with the weighted average reported

Stuelpnagel Reduces Direct Stake in 10x Genomics via Two Same-Day Transactions

According to the filing, John R. Stuelpnagel, listed as a Director of 10x Genomics, Inc., disposed of a total of 20,000 shares of Class A Common Stock on August 11, 2026. Both transactions were coded "S," indicating open-market sales. The filing was signed by Randy Wu as Attorney-in-Fact for John R. Stuelpnagel and dated August 13, 2026.

The first transaction involved 17,000 shares sold at a weighted average price of $57.5812 per share. The filing notes in its explanation of responses that this transaction "was executed in multiple trades at prices ranging from $57.50 to $58.1525." The reporting person has undertaken to provide, upon request, full details of the number of shares sold at each separate price. The second transaction covered 3,000 shares sold at $58.725 per share, with no indication of multiple trade prices for that block.

Following both dispositions, Stuelpnagel's directly held beneficial ownership in Class A Common Stock stood at 348,436 shares, according to the filing. No derivative securities transactions were reported in Table II. The filing does not indicate that a Rule 10b5-1 trading plan was in effect for these transactions, as the corresponding checkbox was not checked.

What Was Disclosed

The Form 4 discloses two open-market sales of 10x Genomics Class A Common Stock by Director John R. Stuelpnagel on August 11, 2026, totaling 20,000 shares, leaving him with 348,436 shares held directly.